EQ
Equillium Inc

4,613
Loading...
Loading...
News
all
press releases
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Business Wire·7mo ago
News Placeholder
More News
News Placeholder
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Business Wire·10mo ago
News Placeholder
Equillium to Present at the Stifel Healthcare Conference
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Business Wire·10mo ago
News Placeholder
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Business Wire·10mo ago
News Placeholder
Equillium Maintains Rights to Itolizumab Following Ono Partnership
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Business Wire·11mo ago
News Placeholder
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Business Wire·11mo ago
News Placeholder
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Business Wire·1y ago
News Placeholder
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on August 30...
Business Wire·1y ago
News Placeholder
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Business Wire·1y ago
News Placeholder
Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Business Wire·1y ago

Latest EQ News

View

Advertisement. Remove ads.

Advertisement. Remove ads.